StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 3.6 %

NYSE:BTX opened at $1.08 on Wednesday. The stock has a market capitalization of $63.53 million, a PE ratio of -0.49 and a beta of 4.61. The stock’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.66. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.